BriaCell Doubles Progression-Free-Survival And Reports Clinical Data Of Bria-IMT ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
BriaCell Therapeutics reported significant clinical data for its Bria-IMT treatment, showing an 83% intracranial objective response rate and doubling the median progression-free survival in heavily pretreated advanced breast cancer patients with CNS metastases.
May 24, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BriaCell Therapeutics' Bria-IMT treatment has shown an 83% intracranial objective response rate and doubled the median progression-free survival in heavily pretreated advanced breast cancer patients with CNS metastases.
The clinical data showing significant improvement in progression-free survival and high intracranial objective response rate is likely to positively impact BriaCell's stock price in the short term as it indicates strong efficacy of their treatment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100